HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
alpha- amino- 2'- chloro- 5- (phosphonomethyl)(1,1'- biphenyl)- 3- propanoic acid
structure given in first source; RN given refers to (S)-isomer
Also Known As:
SDZ 220-581; SDZ 220-581, (R)-isomer; SDZ-220-581
Networked:
2
relevant articles (
1
outcomes,
1
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Hydrocarbons: 1713
Cyclic Hydrocarbons: 97
Aromatic Hydrocarbons: 291
Benzene Derivatives: 17
Biphenyl Compounds: 7
alpha-amino-2'-chloro-5-(phosphonomethyl)(1,1'-biphenyl)-3-propanoic acid: 2
Carboxylic Acids: 973
Acyclic Acids
Propionates: 988
alpha-amino-2'-chloro-5-(phosphonomethyl)(1,1'-biphenyl)-3-propanoic acid: 2
Lipids: 114793
Fatty Acids: 27405
Volatile Fatty Acids: 3052
Propionates: 988
alpha-amino-2'-chloro-5-(phosphonomethyl)(1,1'-biphenyl)-3-propanoic acid: 2
Related Diseases
1.
Seizures (Absence Seizure)
06/01/1996 - "
With the most active agent, SDZ 220-581, full protection against maximal electroshock seizures (MES) was obtained at oral doses of 10 mg/kg in rats and in mice.
"
2.
Parkinson Disease (Parkinson's Disease)
10/31/1996 - "
The present studies investigated whether SDZ 220-581 ((S)-alpha-amino 2'chloro-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoic acid), a potent, competitive antagonist at the NMDA glutamate receptor subtype, reversed haloperidol-induced catalepsy in rats, a widely used model of Parkinson's disease.
"
10/31/1996 - "
Since it has been demonstrate that SDZ 220-581 counters the effects of L-dihydroxyphenylalanine (L-DOPA) on the motor disturbances of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-pre-treated primates, the results suggest that the reversal of haloperidol-induced catalepsy by competitive NMDA receptor antagonists may not be predictive of efficacy in other models of Parkinson's disease.
"
3.
Catalepsy
10/31/1996 - "
The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats.
"
10/31/1996 - "
The present studies investigated whether SDZ 220-581 ((S)-alpha-amino 2'chloro-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoic acid), a potent, competitive antagonist at the NMDA glutamate receptor subtype, reversed haloperidol-induced catalepsy in rats, a widely used model of Parkinson's disease.
"
10/31/1996 - "
Since it has been demonstrate that SDZ 220-581 counters the effects of L-dihydroxyphenylalanine (L-DOPA) on the motor disturbances of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-pre-treated primates, the results suggest that the reversal of haloperidol-induced catalepsy by competitive NMDA receptor antagonists may not be predictive of efficacy in other models of Parkinson's disease.
"
Related Drugs and Biologics
1.
Glutamate Receptors (Glutamate Receptor)
2.
N-Methylaspartate (NMDA)
3.
Propionates
4.
Haloperidol (Haldol)
5.
diphenyl (biphenyl)
6.
N-Methyl-D-Aspartate Receptors (NMDA Receptors)
7.
1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
8.
Levodopa (L Dopa)
9.
Dihydroxyphenylalanine (Dopa)